Medicare GLP-1 Bridge Hits 700K Seniors; Lilly Captures 70% at $245/Month Net — "Very Market-Expansionary"
The Medicare GLP-1 Bridge — the CMS demonstration giving Part D seniors weight-management GLP-1 access at a $50 monthly copay (launched July 1, 2026 under the Trump MFN deals) — is scaling faster than any official update has caught. Eli Lilly CEO David Ricks said on September 23, 2026 that the program has reached ~700,000 seniors who've started treatment, with Lilly capturing 70% of the market — well above its ~60% share of the broader obesity market (FiercePharma).
The enrollment trajectory tells the story: the White House cited 500,000 seniors in its August 31 MFN announcement, CMS Administrator Mehmet Oz updated it to 600,000 the same day, and Ricks put it at 700,000 three weeks later. Ricks: "That's very encouraging—that seniors are talking to their doctors. They want to manage their weight. They understand there's long-term health consequences… It's very market-expansionary, which is what we had hoped."
The economics, per FiercePharma: Lilly supplies its GLP-1s to Medicare at a net price of $245/month. Jefferies analyst Akash Tewari calculates that at a 70% share that's ~$1.4B in annualized revenue today, and if enrollment keeps the current pace, Lilly could exit 2026 at a $3–3.5B annualized run-rate. Ricks also noted physicians are steering the heaviest, most-complicated seniors to Zepbound, while Foundayo (the oral) is pulling in Medicare patients who want convenience over maximum weight loss — Foundayo now takes ~1 in 3 new oral GLP-1 starts. Novo's EVP of US operations Jamey Millar likewise pointed to the Medicare program at the Sep 21 CMD as a key way to expand the patient base (see Novo Strategic Reset Under Doustdar: Post-CMD Buying Spree Continues with $2.6B Hengrui Deal for Once-Weekly Obesity Pill).
Investor takeaway: The Bridge is proving the seniors market is real, incremental demand — "market expansionary" rather than cannibalizing commercial scripts — and it's disproportionately flowing to Lilly. Two overhangs remain: the program's manufacturer-rebate structure and the January 2027 list-price cuts (Ozempic -35%, Wegovy -50%, tracked via watch), which will reset the net-price baseline the Bridge is built on.